Cwm LLC Sells 997 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Cwm LLC trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,301 shares of the company’s stock after selling 997 shares during the period. Cwm LLC’s holdings in Elanco Animal Health were worth $181,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. lifted its holdings in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after buying an additional 1,361 shares during the period. ORG Partners LLC purchased a new position in shares of Elanco Animal Health in the 2nd quarter valued at approximately $31,000. nVerses Capital LLC bought a new stake in shares of Elanco Animal Health during the second quarter valued at approximately $32,000. Quarry LP purchased a new stake in Elanco Animal Health in the second quarter worth $40,000. Finally, Global Financial Private Client LLC bought a new position in Elanco Animal Health in the first quarter worth $72,000. Institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ELAN shares. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. Barclays raised their target price on shares of Elanco Animal Health from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Piper Sandler lowered their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, July 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $17.43.

Insiders Place Their Bets

In related news, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction dated Monday, August 12th. The shares were purchased at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Elanco Animal Health news, Director Michael J. Harrington bought 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the purchase, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 100,000 shares of the company’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. This trade represents a 200.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Down 1.2 %

Shares of ELAN stock opened at $12.51 on Thursday. The company has a 50 day simple moving average of $14.43 and a two-hundred day simple moving average of $14.85. The stock has a market cap of $6.18 billion, a P/E ratio of -4.77, a P/E/G ratio of 1.53 and a beta of 1.40. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.18 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.